Novo Nordisk (NVO) Hit By Lowered Guidance

Group 1 - GreensKeeper Asset Management reported a +4.0% gain for its Value Fund in Q3 2025, with a year-to-date return of +0.2% net of fees and expenses [1] - The US dollar negatively impacted performance by -3.7% year-to-date, while the market rally was primarily driven by AI, crypto, and speculation [1] - The fund's top 5 holdings can be reviewed to identify its best investment picks for 2025 [1] Group 2 - Novo Nordisk A/S (NYSE:NVO) experienced a one-month return of -0.08% and a significant 53.79% loss in value over the last 52 weeks, closing at $48.96 per share with a market capitalization of $217.553 billion on December 16, 2025 [2] - Novo Nordisk A/S was the second-largest detractor for the fund in Q3 2025, with a decline of -19.6%, attributed to lowered guidance due to factors such as competition and slower market expansion for obesity treatments [3] - Despite being held by 50 hedge fund portfolios at the end of Q3, the company is not among the 30 most popular stocks among hedge funds, with the potential for AI stocks being viewed as offering greater upside potential [4]